• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
XU Zhilong,CHEN Yina,WU Mei,DU Feng,MA Yanyan.The clinical analysis of dessicabine combined with CAG in the treatment of senile acute myeloid leukemia[J].Journal Of Pharmaceutical Research,2020,39(8):491-493,496[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2777times   Download 2521次 QR Code for this article
Scan with your phone!
地西他滨联合CAG方案治疗老年急性髓系白血病的临床分析
徐芝龙,陈以娜,吴梅,杜凤,马艳艳
Font:Larger+|Default|Smaller-
(兰陵县人民医院血液科,山东 临沂 277700)
摘要:
目的 探讨老年髓系随性白血病患者的不同治疗方式及其疗效。方法 于2018年1月开展为期1年的研究,并在研究期间随机选取我院住院治疗的白血病患者作为案例探究最佳疗法。所有患者均被确诊为髓系白血病,在确诊同时将患者纳入到试验组与常规组。常规组单纯应用CAG治疗方案(阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子),试验组采用地西他滨结合CAG的治疗方案。以康复效果、不良反应以及生存质量等进行对比研究。结果 试验组疗效显著优于常规组,P<0.05;试验组不良反应发生率明显少于常规组,P<0.05;干预之前两组患者的免疫指标无明显差异,数据之间的对比无意义,P>0.05;不同方案治疗后试验组免疫指标明显高于常规组,患者免疫指标改善效果突出,适用于统计学标准,P<0.05;试验组患者的平均生存率、疾病与事件相关生存期的数据均显著优于常规组,数据之间的差异较大且有意义,P<0.05。结论 为髓系白血病患者提供CAG、地西他滨的结合方案具备显著干预效果,可以有效改善患者的临床症状并延长患者生存时间、提升生存质量,值得推广普及。
关键词:  急性髓系白血病  地西他滨  CAG方案  临床疗效
DOI:10.13506/j.cnki.jpr.2020.08.014
基金项目:
The clinical analysis of dessicabine combined with CAG in the treatment of senile acute myeloid leukemia
XU Zhilong,CHEN Yina,WU Mei,DU Feng,MA Yanyan
(Department of Hematology,People's Hospital of Lanling County,Linyi 277700,China)
Abstract:
Objective To explore the different treatment methods and curative effects of elderly patients with myelogenous leukemia.Methods A one-year study was carried out in January 2018. During the study, the leukemia patients in our hospital were randomly selected as cases to explore the best treatment. All the patients were diagnosed as myeloid leukemia. At the same time, the patients were included in the experimental group and the conventional group. The conventional group was treated with CAG alone, and the experimental group was treated with dessicabine combined with CAG. The effects of rehabilitation, adverse reactions and quality of life were compared.Results The curative effect of the experimental group was significantly better than that of the conventional group (P Standard, P<0.05;The average survival rate, disease and event-related survival data of the experimental group were significantly better than those of the conventional group, and the difference between the data was significant, P<0.05.Conclusion The combination of CAG and dessicabine for patients with myeloid leukemia has a significant intervention effect, which can effectively improve the clinical symptoms, prolong the survival time and improve the quality of life of patients. It is worth popularizing.
Key words:  Acute myeloid leukemia  Dessicabine  CAG regimen  Clinical efficacy
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.